| 1 |
26424559 | Implications of NQO1 in cancer therapy. | 2015 Nov |
1 |
| 2 |
21250978 | The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase. | 2011 Jun |
6 |
| 3 |
18794327 | Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). | 2008 Dec |
2 |
| 4 |
17015278 | The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells. | 2006 Sep |
4 |
| 5 |
15746574 | Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction. | 2005 Apr |
2 |
| 6 |
15131056 | Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1. | 2004 May 1 |
2 |
| 7 |
15554240 | Quinone reductases multitasking in the metabolic world. | 2004 Oct |
2 |
| 8 |
14666706 | Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts. | 2003 Sep-Oct |
1 |
| 9 |
11248489 | Stability-indicating HPLC assay and solution stability of a new diaziridinyl benzoquinone. | 2001 Mar |
1 |
| 10 |
10718341 | Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. | 2000 Apr 1 |
2 |
| 11 |
9865924 | A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. | 1998 Dec |
4 |